Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis
Authors' conclusion
Cardiometabolic drugs show a significant beneficial effect on EAT reduction. GLP-1 RA was more effective than SGLT2-i, while statins had a rather mild effect. We believe that the most effective treatment with these drugs should target younger patients with high BMI.
Study context
- Population
- Patients treated with cardiometabolic drugs with epicardial adipose tissue (EAT) assessment
- Participants
- 1,064 patients18 studies
- Comparison
- Cardiometabolic drugs and EAT reduction
- Outcome
- EAT reduction
Methodological detailsPRISMA guidelines, meta-regression, sensitivity analysis
- PRISMA guidelines
- Meta-regression
- Sensitivity analysis
Pooled result
As reported in the abstract
| Group | SMD | p |
|---|---|---|
| GLP-1 RA | - 1.005 | p < 0.001 |
| SGLT2-i | - 0.552 | p < 0.001 |
| Statins | - 0.195 | p < 0.001 |
SMD
GLP-1 RA- 1.005
SGLT2-i- 0.552
Statins- 0.195
p
GLP-1 RAp < 0.001
SGLT2-ip < 0.001
Statinsp < 0.001
Further pooled results
EAT thickness measured by US (sensitivity analysis), all drugs
- Overall SMD
- - 0.663; 95%CI - 0.79, - 0.52; p < 0.001
- Sensitivity analysis
Meta-regression: effect modifiers of EAT reduction (composite effect and EAT thickness, respectively)
- Younger age
- Z: 3.99; p < 0.001 and Z: 1.97; p = 0.001
- Higher BMI
- Z: - 4.40; p < 0.001 and Z: - 2.85; p = 0.004
Original publication
Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. Cardiovasc Diabetol. Published 31 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →